Arbutus Biopharma Corporation (ABUS)

[Ubertino]

In re MC3

In March, Tekmira filed a lawsuit charging Alnylam with misappropriating and misusing trade secrets and other confidential information related to its core lipid nanoparticle technology (GSN 3/17/2011).

At the time, Tekmira's President and CEO Mark Murray said that Alnylam had applied for patents based on Tekmira's proprietary technology and that Alnylam “stole” a new lipid delivery approach dubbed MC3.

Alnylam countersued, and charged that Tekmira had violated its agreements with Alnylam by ignoring contractual “confidential and non-public alternative dispute-resolution procedures” (GSN 4/7/2011).

This week, Maraganore said that “we believe this action is fully without merit or foundation, and in our view, it is nothing short of an unwarranted act.” He declined to elaborate.

http://www.investorvillage.com/smbd.asp?mb=569&mn=28078&pt=msg&mid=10457175